upadacitinib


( Last Updated : September 16, 2022)
Generic Name:
upadacitinib
Project Status:
Pending
Therapeutic Area:
ankylosing spondylitis
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Rinvoq
Project Line:
Reimbursement Review
Project Number:
SR0759-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of adults with active ankylosing spondylitis who have had an inadequate response to a biologic DMARD or when use of those therapies is inadvisable.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Rinvoq is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response to a biologic DMARD or when use of those therapies is inadvisable.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.